Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.52 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 3/20 | 0.48 |
| ▸ | CCR4 | P51679 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 2/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556839 | 1.00 | ALPL (0.56) | ALPLPIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL791102 | 0.91 | ALPL (0.52) | ALPLPIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL29556249 | 0.91 | ALPL (0.52) | ALPLPIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL15459550 | 0.90 | ALPL (0.51) | ALPLPIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL28554047 | 0.90 | ALPL (0.51) | ALPLPIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL15462778 | 0.90 | ALPL (0.51) | ALPLPIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL789981 | 0.89 | ALPL (0.48) | ALPLPIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL15650005 | 0.89 | ALPL (0.50) | ALPLPIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL22508714 | 0.89 | ALPL (0.50) | ALPLPIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL15559069 | 0.89 | ALPL (0.52) | ALPLPIK3CGPIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112794851-B | 3- (pyridine-3-yl) -7-azaindole derivative PI3K delta inhibitor and preparation method and application thereof | 复旦大学 | 2022-08-23 | — | — | CN | disclosed |
| CN-112724134-B | Azaindazole bipyridine derivative myeloid cell proliferation inhibitor, preparation method and application thereof in pharmacy | 复旦大学 | 2022-04-01 | — | — | CN | disclosed |
| CN-113214247-A | Azaindole derivative marrow cell proliferation inhibitor, preparation method and application thereof in pharmacy | 复旦大学 | 2021-08-06 | — | — | CN | disclosed |
| CN-112794851-A | 3- (pyridine-3-yl) -7-azaindole derivative PI3K delta inhibitor and preparation method and application thereof | 复旦大学 | 2021-05-14 | — | — | CN | disclosed |
| CN-112724134-A | Azaindazole bipyridine derivative myeloid cell proliferation inhibitor, preparation method and application thereof in pharmacy | 复旦大学 | 2021-04-30 | — | — | CN | disclosed |
| EP-3053926-B1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2018-08-08 | — | — | EP | disclosed |
| US-9745321-B2 | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2017-08-29 | — | — | US | disclosed |
| US-9745321-B2 | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2017-08-29 | — | — | US | disclosed |
| US-20160214994-A1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2016-07-28 | — | — | US | disclosed |
| US-20160214994-A1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2016-07-28 | — | — | US | disclosed |
| WO-2015120737-A1 | SUBSTITUTED PYRIDOPYRIMIDINE COMPOUNDS, PREPARATION METHODS THEREFOR AND USES THEREOF | 北大方正集团有限公司 | 2015-08-20 | — | — | WO | disclosed |
| WO-2014022128-A1 | PI3 KINASE MODULATORS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20140038991-A1 | Protein Kinase Inhibitors | ASTAR BIOTECH LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038991-A1 | Protein Kinase Inhibitors | ASTAR BIOTECH LLC (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2012174312-A2 | BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214994-A1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | PIK3CA, WEE1, TKFC | ALPL 1128/4885PIK3CG 8/4885PIK3CA 1/4885 |
| US-20140038991-A1 | Protein Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K7 | ALPL 2923/4885PIK3CG 450/4885PIK3CA 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.